Preview

Артериальная гипертензия

Расширенный поиск

Проблема хронической болезни почек в современной медицине

https://doi.org/10.18705/1607-419X-2006-12-3-185-193

Полный текст:

Аннотация

В обзоре представлена концепция хронической болезни почек (ХБП) в современной нефрологии. Обсуждаются новые данные о структуре факторов риска развития дисфункции почек и кардиоренальных отношениях. Подчеркивается необходимость одновременного проведения мероприятий по кардио- и ренопротекции.

Об авторах

А. В. Смирнов
Научно-исследовательский институт нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова
Россия


В. А. Добронравов
Научно-исследовательский институт нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова
Россия


И. Г. Каюков
Научно-исследовательский институт нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова
Россия


Список литературы

1. Смирнов A.B., Каюков И.Г., Есаян A.M. и др. Превентивный подход в современной нефрологии. Нефрология 2004;. 8(3):- 7-14

2. Смирнов A.B., Есаян A.M., Каюков И.Г. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 11-17

3. National Kidney Foundation KD: Clinical practice guidelines for chronic Kidney disease: Evaluation, classification and stratification. AmJ Kidney Dis 2002;39 [Suppl 1J: S1-S266

4. Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 1998; 32(1): 23-31

5. Cockcroft D.W., Gault M.H. Prediction of creatinine from serum creatinine. Nephron 1976;16(1);.31-41

6. Levey A.S., Bosch J.P., Lewis J.B. A more accurate method to estimate glomerular filtration rate from serum creatinine; a new prediction equation. Ann Intern Med 1999;. 130(8): 461-470

7. Есаян A.M. Тканевая ренин-ангиотензиновая система почки. Новая стратегия нефропротекции. Нефрология 2002; 6(3): 8-16

8. Каюков И.Г., Есаян A.M., Кучер А.Г., Ермаков Ю.А. Роль функционально-гемодинамическтх механизмов в прогрессировании хронического гломерулонефрита. Нефрология 1998; 2(1): 7-13

9. Смирнов A.B. Дислииопротеидемии и проблемы нефропротекции. Нефрология 2002; 6(2): 8-14

10. Рентц Дун Б., Андерсон Ш., Бреннер Б. Гемодинамичес-кие основы прогрессирования почечных болезней. Современная нефрология. II международный нефрологический семинар. М., 1997; 162-172

11. Schiepati A., Remuzzi G. Chronic renal disease as a public health problem: Epidemiology, social and economic implications. Kidney Int 2005; 68 [Suppl 98J: S7-S10

12. Jones C.A., McQuillan G.M., Kusek J.W. et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. AmJ Kidney Dis 1998; 32: 992-999

13. Coresh J., Astor B.C., Greene T. et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41(1): 1-12

14. Locatelli F., Del Vecchio L., Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol. Dial. Transplant 2002; 17 [Suppl 11]: 2-7

15. Chen J., Munter P., Hamm L.Z. et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-174

16. Verhave J.C., Gansevoort R.T., Hillege H.L. et al., for the PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in general population. Kidney In. 2004;. 66[Supp. 92]: S18-S21

17. Atkins R.C. The epidemiology of chronic kidney disease. Kidney Int 2005; 67[Suppl 94]: S14-S18

18. Iseki K., Iseki C., Ikemmiya Y. et al. Risk of development end-stage renal disease in a cohort mass screening. Kidney Int 1996; 49: 800-805

19. Добронравов B.A., Смирнов A.B., Драгунов С.В. и др. Эпидемиология хронической болезни почек в Вологодской области. Нефрология 2004; 8(1): 36-41

20. Добронравов В.А., Смирнов A.B., Драгунов С.В. и др. Эпидемиология хронической почечной недостаточности в Северо-Западном регионе России: на пути к созданию регистра хронической почечной болезни. Тер арх 2004; 76(9): 57-61

21. Смирнов A.B., Добронравов В.А., Бодур-Ооржак А.Ш. и др. Эпидемиология и факторы риска хронических болезней почек: региональный уровень общей проблемы. Тер арх 2005; (6): 20-27

22. Смирнов A.B., Добронравов В.А., Бодур-Ооржак А.Ш. и др. Распространенность и заболеваемость поздними стадиями хронической болезни почек в Республике Тыва. Нефрология 2005; 9(4): 25-29

23. Moeller S., Gioberge S., Brown G. ESRD patients in 2001: Global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002; 17: 2071-2076

24. Jones C.A., Krolewski A.S., Rogus J. et al. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 2005; 67(5): 1684-1691

25. United States Renal Date System. Annual date report, 2004

26. De Vecchi A.F., Drratwa M., Weidemann M.E. Healthcare system and end-stage renal disease (ESRD) therapies - an international review. Costs and reimbursement/funding of ERSD therapies. Nephrol Dial Transplant 1999; 14 [Suppl 6]: 31-41

27. Мухин Н.А., Балкаров И.М., Моисеев В.С. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Тер арх 2004; 76(9): 5-10

28. Chi-Yuan Hsu, Lin F., Vittinghoff E., Shlipac M.G. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United State. J Am Soc Nephrol2003; 14: 2902-2907

29. McClellan W.M., Flanders W.D. Risk factors for progressive chronic kidney disease. J Am Soc Nephro 2003; 14: S65-S70

30. Добронравов B.A. Эпидемиология диабетической нефропатии: общие и региональные проблемы. Нефрология 2002; 6(1):.16-22

31. Perera G.A. Hypertensive vascular disease: description and natural history. J Chron Dis 1955; 1: 33-42

32. Ruelope Z.M., Salvetti A., Jamerson К. et al. Renal function and intensive lowering of blood pressure iu hypertensive participants of the hypertension optimal treatment (HOJ) study. J Am Soc Nephrol 2001; 12: 218-225

33. Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomized to double-blind treatment with long- acting calcium- channel blocker or diuretic in International Nifidipine GITS study: Intervention as a goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356(9228): 366-372

34. Haroun N.K., Jaar B.G., Hoffman S.C. et al. Risk factors for chronic Kidney disease: a prospective study of 23.534 men and women in Washington Country, Maryland. J Am Soc Nephrol 2003; 14: 2934- 2941

35. United States Renal Date System. Annual date report, 2001

36. United States Renal Data System. Annual date report, 2002

37. Reyes D., Lew S.Q., Kimmel P.L. Gender differences in hypertension and kidney disease. Med Clin North Am 2005; 89(3): 613-630

38. Iseki K., Nakai S., Shinzato T. et al. Increasing gender difference in the incidence of chronic dialysis therapy in Japan. Ther Apher Dial 2005; 9(5): 407-411

39. Eriksen B.O., Ingebretsen О.С. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 2006; 69 (2): 375-382

40. Lemos C.C.S., Mandarin-de-Lacerda A., Dorigo D. et al. Chronic renal failure in male and female rats. J Nephrol 2005; 18(4): 368-373

41. Stengel B., Tarver-Carr M.E., Powe N.R. et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003; 14(4): 479-487

42. Kramer H., Luke A., Bidani A. et al. Obesity and prevalent and incident CKD: the hypertension detection and follow-up program. AmJ Kidney Dis 2005; 46(6): 587-594

43. de Jong P.E., Verhave J.C., Pinto- Siestma S.J. et al. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 26 [Suppl 4]: S21- S24

44. Verhave J.C., Hillege H.Z., Burgerhof G.M. et al. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005; 67: 1967- 1973

45. Краснова E.A., Моисеев С.В., Фомин В.В. Нефрологичес-кие аспекты проблемы ожирения. Клин мед 2005; 83(4): 9- 14

46. Fried Z.F., Orchard T.J., Kasiske B.Z. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260- 269

47. Schaeffner E.S., Kurth T., Curhan G.C. et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14:084- 2091

48. Muntner P., Coresh J., Smith J.C. et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293- 301

49. Tanaka H., Shiohira Y., Uezu Y. et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69(2):369-374

50. Pinto-Siersma S.J., Mulder J., Janssen W.M. et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133:585- 591

51. Warmoth L., Regalado M.M., Simoni J. et al. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. Am J Med Sei 2005; 330(3): 111-119

52. Linder A., Charka B., Sherrazd D.J., Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Eng. J Med 1974. 290: 679- 701

53. Foley R.N., Parfrey P.S., Sarnak M.J. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 [Suppl 12:. S16- S23

54. Смирнов A.B., Добронравов B.A., Каюков И.Г. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005;9(3): 7-15

55. Кутырина И.М., Руденко Т.Е., Дзигоева М.Ю. Ремоделирование сосудов при хронической почечной недостаточности. Клин мед 2005;(2): 16-21

56. Majunath G., Tighionart H., Ibrahim H. et al. Level of kidney function as a risk factors for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47- 55

57. Henry R.M., Kostense P.J., Bos G. et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62: 1402- 1407

58. Nitsch D., Dietrich D.F., von Eckardstein A. et al. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. Nephrol Dial Transplant 2006; 21(4): 935-944

59. Segura J., Campo C., Ruilope L.M. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int Suppl. 2004 (92):S45-9.2004

60. Mann J.F.E. Cardiovascular risk in patients with mild renal insufficiency: implication for the use of ACE inhibitors. La Presse Medicale 2005; 34(18): 1303-1308

61. Mann J.F., Gerstein H.C., Pogue J., Bosch J., Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of rainipril: the HOPE randomized trial. Ann Intern Med 2001:134: 629-636

62. Al Suwaidi J., Reddan D.N., Williams К. et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002; 106: 974-980

63. McCullough P.A., Soman S.S., Shah S.S. et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol. 2000;36(3): 679-684

64. Hillege H.L., van Gilst V.H., van Veldhuisen D.J. et al. Randomized trial. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefit of ACE inhibition: the CAST randomized trial. Eur Heart J 2003; 24: 412-420

65. Tonelli M., Jose P., Curhan G. et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of previously conducted randomized trial. BMJ 2006; 332(7555): 1426-1432

66. Ritz E., Dikow R., Ruilope L.M. Renal dysfunction as a cardiovascular risk factor. Curr Hypertens Rep 2002; 4. 365- 368

67. Halimi J.M., Forhan A., Balkan B. et al. Ig microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk 2001; 8: 139- 146

68. Orth S.R. Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663- 1672

69. Stuveling E.M., Bakker S.J., Hilige H.X. et al. Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 2005; 20: 497- 508

70. Bassuk S.S., Ritai N., Ridker P.M. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29: 439-493

71. Anavekar N.S., Pfeffer M.A. Cardiovascular risk in chronic kidney disease. Kidney Int 2004; 66 [Suppl 92]: S11- S15

72. Zoccali C. Biomarkers in chronic kidney disease: utility and issues towards better understanding. Curr Opin Nephrol Hypertens 2005;14 (6):532-537

73. Annuk M., Soveri I., Zilmer M. et al. Endothelial function, CRP and oxidative stress in chronic kidnev disease. J Nephrol. 2005;18(6):721-726

74. Romao J.E. Jr, Haiashi A.R., Elias R.M. et al. Positive acute-phase inflammatory markers in different stages of chronic kidney disease. Am J Nephrol. 2006; 26(1): 59-66

75. Locatelli F., Pozzoni P., Del Vecchio L. Epidemiology of chronic kidney disease in Italy: Possible therapeutical approaches. J Nephrol 2003; 16: 1-10

76. Muntner P., He J., Astor B.C. et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005; 16:529-538

77. Stuveling E.M., Hillege H.L., Bakker S.J. et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003; 63:654-661

78. Silverberg D.S., Wexler D., Iaina A.The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?J Nephrol. 2004;17(6):749-761

79. Добронравов В.А., Жлоба А.А., Трофименко И.И. Гипер-гомоцистеинемия как системная проблема с точки зрения нефролога. Нефрология 2006; 10(2): 7-17

80. Yang F., Tan Н-М., Wang H. Hyperhomocysteinemia and atherosclerosis. Acta Physiol Sin 2005; 57(2): 103-114

81. Goligorsky M.S. Endothelial cell dysfunction: can’t live with it, how to live without it. Am J Physiol Renal Physiol 2005; 288: 871-880

82. Смирнов A.B., Добронравов B.A., Голубев P.B. и др. Распространенность гипергомоцистеинемии в зависимости от стадии хронической болезни почек. Нефрология.2005;9(2):48-52

83. Смирнов A.B., Добронравов В.А., Неворотин А.И. и др. Гомоцистеин вызывает повреждения не только клубочкового, но и канальцевого отдела нефрона (экспериментальное исследование) Нефрология.2005;9(3): 81-87

84. Смирнов A.B., Добронравов В.А., Неворотин А.И. и др. Гипергомоцистеинемия усугубляет повреждения нефрона при экспериментальной хронической почечной недостаточности. Нефрология 2004; 9(4): 67-74

85. Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер арх 2004; (6):39-46

86. Есаян A.M. Тканевая ренин-ангиотензиновая система почки. Новая стратегия нефропротекцни. Нефрология 2002; 6(3): 8-16

87. Burgess E.D., Carides G.W., Gerth W.C. et al. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from Canadian perspective. Can J Cardiol 2004; 20(6): 613-618

88. Brenner B.M., Cooper M.E., De Zeew D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869 88. Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of theclinical trial evidrnce. Clin Ther 2003; 25(12): 3044-306413

89. Fouque D., Wang P., Laville M., Boissel J.P. Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure. Nephrol Dial Transplant 2000; 15: 1986-1992

90. Hayashi T., Suzuki A., Shoji T. et al. Cardiovascular effect of normalizing the hematocrit level during erythropoethin in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256

91. Jafar T.H., Schmid C.H., Landa M. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87;

92. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860;

93. Locatelli F., Del Vecchio L. How long can dialysis be postponed by low protein diet and ACE ihibitors? Nephrol Dial Transplant-1999; 1360-1364;

94. Locatelli F., Del Vecchio L., D’Amico M., Andrulli S. Is it the agent or the pressure level that matters for renal protection in chronic nephropathies? J Am Soc Nephrol 2002; 13 [Suppl. 18


Для цитирования:


Смирнов А.В., Добронравов В.А., Каюков И.Г. Проблема хронической болезни почек в современной медицине. Артериальная гипертензия. 2006;12(3):185-193. https://doi.org/10.18705/1607-419X-2006-12-3-185-193

For citation:


Smimov A.V., Dobronravov V.A., Kayukov I.G. The problem of chronic kidney disease in current medicine. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2006;12(3):185-193. (In Russ.) https://doi.org/10.18705/1607-419X-2006-12-3-185-193

Просмотров: 101


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)